Gestational diabetes mellitus (GDM) is any degree of glucose intolerance with onset or first recognition during pregnancy.
Hyperglycemia in pregnancy may be suggested by the presence of glycosuria, a fetus that is large for date, or polyhydramnios.
Overt diabetes mellitus may be found in women presenting with risk factors for type 2 diabetes during the first prenatal visit (before 13 weeks of gestation).
Initiating interventions combining diet and physical activity between 9 and 16 weeks of gestation may attenuate weight gain but not successfully avert the development of gestational diabetes mellitus, according to data from the LIFE-Moms consortium.
Having a diabetes prior to pregnancy and, to a lesser extent, gestational diabetes mellitus contribute to an increased risk of several subtypes of congenital anomalies in newborns, as reported in a study.
Undergoing in-facility physical activity (PA) programmes initiated before the 20th week of gestation helps reduce the risk of developing gestational diabetes mellitus (GDM) among high-risk mothers, according to the results of a meta-analysis.
Women with high levels of very low-density lipoprotein cholesterol or high apolipoprotein B to A-1 ratio may fare better with insulin than metformin, with a recent study showing that treatment with the latter leads to higher serum concentrations of triglyceride-rich lipoproteins in the last trimester of pregnancy.
Women who follow a healthy plant-based diet before pregnancy have a lower risk of developing gestational diabetes mellitus (GDM), suggests a large, prospective cohort study presented at the ADA 2020 Annual Meeting.
For working expectant moms with gestational diabetes mellitus (GDM) who need additional support to control their blood sugar, a GDM management smartphone app is the way to go, according to a Singapore study.
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa,
08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.